专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060280795A1 Specific time-delayed burst profile delivery system 审中-公开
标题翻译：具体的延时突发配置文件传送系统
公开(公告)号：US20060280795A1
公开(公告)日：2006-12-14
申请号：US11147388
申请日：2005-06-08
申请人： Adel Penhasi , Mila Gomberg , Maxim Gomberg
发明人： Adel Penhasi , Mila Gomberg , Maxim Gomberg
IPC分类号： A61K9/24
CPC分类号： A61K9/2886 , A61K9/4891
摘要： The invention provides a delivery device for the delayed release of an active agent in the gastrointestinal tract comprising a core, comprising an active agent; a first outer coating, comprising a relatively hydrophobic substantially water insoluble polymer having substantially water insoluble hydrophilic particles embedded therein; and a first inner coating layer, comprising an agent that can cause the dissolution of at least one of the water insoluble components of the outer coating, and optionally a water soluble polymer, such that the insoluble particles in the outer coating, upon absorption of liquid, form channels leading to the inner coating layer, thus enabling the dissolution thereof, whereby the agents contained therein are released to cause the dissolution and/or degradation (destruction) of the outer coating, and the release of the pharmaceutically acceptable active agent from the core of the device.
摘要翻译：本发明提供了用于在胃肠道中延迟释放活性剂的递送装置，其包含核心，其包含活性剂; 第一外涂层，其包含相对疏水的基本上不溶于水的聚合物，其中嵌有基本上不溶于水的亲水性颗粒; 以及第一内涂层，其包含可引起外涂层的至少一种水不溶性组分和任选的水溶性聚合物的溶解的试剂，使得外涂层中的不溶性颗粒在吸收液体时形成通向内涂层的通道，从而使其溶解，由此其中所含的试剂被释放以引起外涂层的溶解和/或降解（破坏），并且药学上可接受的活性剂从设备的核心

2. 发明申请

US20060057204A1 Pharmaceutical compositions containing venlafaxine 审中-公开
标题翻译：含有文拉法辛的药物组合物
公开(公告)号：US20060057204A1
公开(公告)日：2006-03-16
申请号：US10532407
申请日：2003-10-23
申请人： Adel Penhasi , Mila Gomberg , Avi Avramoff
发明人： Adel Penhasi , Mila Gomberg , Avi Avramoff
IPC分类号： A61K9/24
CPC分类号： A61K31/135 , A61K9/1635 , A61K9/1652 , A61K9/2077 , A61K9/286 , A61K9/2866 , A61K9/2886 , A61K9/5036 , A61K9/5042
摘要： The invention provides a delayed burst release formulation comprising a core formed as a compressed tablet and an outer coating that surrounds the core; said core comprising venlafaxine, or a pharmaceutically acceptable salt thereof, at least one burst controlling agent and a disintegrant; and said outer coating comprising a water insoluble hydrophobic carrier and water-insoluble but hydrophilic particulate matter.
摘要翻译：本发明提供一种延迟的爆发释放制剂，其包含形成为压制片剂的核心和围绕该核心的外部涂层; 所述核心包含文拉法辛或其药学上可接受的盐，至少一种爆发控制剂和崩解剂; 并且所述外涂层包含水不溶性疏水性载体和水不溶但不亲水的颗粒物质。

3. 发明授权

US09757338B2 Sustained-release donepezil formulation 有权
公开(公告)号：US09757338B2
公开(公告)日：2017-09-12
申请号：US13036010
申请日：2011-02-28
申请人： Adel Penhasi , Mila Gomberg
发明人： Adel Penhasi , Mila Gomberg
IPC分类号： A61K9/20 , A61K9/28 , A61K31/445 , A61K47/38 , A61K9/16 , A61K47/32 , A61K47/34
CPC分类号： A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/2027 , A61K9/2031 , A61K9/205 , A61K9/2846 , A61K9/2853 , A61K9/2866 , A61K31/445 , A61K47/32 , A61K47/34 , A61K47/38
摘要： A sustained-release formulation for an acetylcholinesterase inhibitor, comprising an acetylcholinesterase inhibitor and at least two gel-forming polymers, and methods of manufacture thereof. The acetylcholinesterase inhibitor preferably comprises donepezil.

4. 发明申请

US20110237623A1 SUSTAINED-RELEASE DONEPEZIL FORMULATION 有权
标题翻译：持续释放多奈哌齐配方
公开(公告)号：US20110237623A1
公开(公告)日：2011-09-29
申请号：US13036010
申请日：2011-02-28
申请人： Adel Penhasi , Mila Gomberg
发明人： Adel Penhasi , Mila Gomberg
IPC分类号： A61K31/445 , A61K47/06 , A61K47/36 , A61K47/38 , A61K47/12 , A61P25/28
CPC分类号： A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/2027 , A61K9/2031 , A61K9/205 , A61K9/2846 , A61K9/2853 , A61K9/2866 , A61K31/445 , A61K47/32 , A61K47/34 , A61K47/38
摘要： A sustained-release formulation for an acetylcholinesterase inhibitor, comprising an acetylcholinesterase inhibitor and at least two gel-forming polymers, and methods of manufacture thereof. The acetylcholinesterase inhibitor preferably comprises donepezil.
摘要翻译：包含乙酰胆碱酯酶抑制剂和至少两种凝胶形成聚合物的乙酰胆碱酯酶抑制剂的持续释放制剂及其制备方法。乙酰胆碱酯酶抑制剂优选包含多奈哌齐。

5. 发明申请

US20100297226A1 MULTIPLE UNIT PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：多部门药物制剂
公开(公告)号：US20100297226A1
公开(公告)日：2010-11-25
申请号：US12227864
申请日：2007-06-03
申请人： Adel Penhasi , Sheera Moses-Heller , Mila Gomberg , Avi Avramoff
发明人： Adel Penhasi , Sheera Moses-Heller , Mila Gomberg , Avi Avramoff
IPC分类号： A61K31/4439 , A61K9/20 , A61K9/28 , A61K9/40 , A61K31/4184 , A61P1/04
CPC分类号： A61K9/2886 , A61K9/2077 , A61K9/5026 , A61K9/5042 , A61K31/4439
摘要： An orally disintegratable benzimidazole formulation, featuring a plurality of compressed pellets in a MUPS tablet. The individual units feature a substrate with the active ingredient and an enteric coating, optionally with a subcoating between the substrate and the enteric coating. The individual units are preferably at least partially coated with an outer coating which features a stress absorber, thereby enabling the pellets to be compressed without disturbing the integrity of the enteric coating. The enteric coating preferably does not feature a plasticizer.
摘要翻译：口服崩解的苯并咪唑制剂，其特征在于MUPS片剂中的多个压缩颗粒。单个单元具有含有活性成分的底物和肠溶衣，任选地在底物和肠溶衣之间具有底衣。各个单元优选地至少部分地涂覆有具有应力吸收体的外涂层，从而使得可以压缩颗粒而不干扰肠溶衣的完整性。肠溶衣优选不具有增塑剂。

6. 发明申请

US20100055173A1 RELEASE OF STATINS IN THE INTESTINE 审中-公开
标题翻译：释放INTESTINE中的统计数据
公开(公告)号：US20100055173A1
公开(公告)日：2010-03-04
申请号：US12445016
申请日：2007-10-09
申请人： Adel Penhasi , Maxim Gomberg
发明人： Adel Penhasi , Maxim Gomberg
IPC分类号： A61K9/52 , A61K31/47 , A61K31/366 , A61K31/505 , A61K31/40 , A61K31/404 , A61K31/351 , A61P9/10
CPC分类号： A61K9/2886 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/282 , A61K9/284 , A61K9/2866
摘要： The present invention provides a controlled absorption formulation in which modified release of the active ingredient preferentially occurs in the lower gastrointestinal tract, including the colon. The formulation supports a significantly higher bioavailability of the active ingredient in the body of the subject than that can be achieved from the currently used conventional formulation, such that therapeutically significant plasma levels of statin are maintained for an extended period after administration. The formulation preferably features a core, a subcoat surrounding the core comprising at least one water soluble hydrophilic carrier and an outer coating. The core is optionally and preferably in the form of a tablet.
摘要翻译：本发明提供了一种受控吸收制剂，其中活性成分的改性释放优先发生在下胃肠道，包括结肠中。所述制剂支持所述受试者的活性成分比目前使用的常规制剂可显着提高活性成分的生物利用度，使得在给药后长时间维持治疗上显着的他汀类血浆水平。制剂优选具有核心，围绕核心的底涂层包含至少一种水溶性亲水载体和外涂层。芯可选地优选为片剂的形式。

7. 发明申请

US20060251720A1 Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins 审中-公开
标题翻译：他汀类药物在胃肠道局部控制吸收，达到高血糖的他汀类药物
公开(公告)号：US20060251720A1
公开(公告)日：2006-11-09
申请号：US11305544
申请日：2005-12-15
申请人： Adel Penhasi , Maxim Gomberg
发明人： Adel Penhasi , Maxim Gomberg
IPC分类号： A61K31/401 , A61K31/366 , A61K31/22 , A61K9/22
CPC分类号： A61K31/366 , A61K9/2027 , A61K9/2054 , A61K9/2077 , A61K9/2846 , A61K9/2866 , A61K9/2886 , A61K31/22 , A61K31/401
摘要： The present invention relates to a localized controlled absorption formulation of a statin in which rapid release of the active ingredient preferentially occurs in the lower gastrointestinal tract including the colon. The formulation provides significantly higher blood level concentration and bioavailability of the active ingredient in the body of a subject as compared to the bioavailability achieved from the currently available conventional formulations The blood levels are maintained for a significantly longer period of time as compared with currently available conventional formulations. The formulation preferably includes a core, over which an outer coating is layered. The core preferably includes a burst controlling agent and optionally a disintegrant. The outer coating includes a water insoluble polymer and at least one water permeable agent allowing entry of water into said core, the water permeable agent comprising hydrophilic particulate matter. The core is preferably in the form of a tablet.
摘要翻译：本发明涉及他汀类的局部受控吸收制剂，其中活性成分的快速释放优先发生在包括结肠的下胃肠道中。与目前可获得的常规制剂相比，该制剂提供了与受试者体内活性成分相比显着更高的血液浓度和生物利用度。与目前可获得的常规制剂相比，血液水平维持较长的时间配方。该制剂优选包括芯，在其上分层外涂层。核心优选包括爆发控制剂和任选的崩解剂。外涂层包括水不溶性聚合物和允许水进入所述核心的至少一种水可渗透剂，所述水可渗透剂包含亲水性颗粒物质。核心优选为片剂的形式。

8. 发明申请

US20110038933A1 STABLE BENZIMIDAZOLE FORMULATION 审中-公开
标题翻译：稳定的苯并咪唑配方
公开(公告)号：US20110038933A1
公开(公告)日：2011-02-17
申请号：US12866255
申请日：2009-05-05
申请人： Valerie Azoulay , Avi Avramoff , Adel Penhasi , Maxim Gomberg
发明人： Valerie Azoulay , Avi Avramoff , Adel Penhasi , Maxim Gomberg
IPC分类号： A61K9/28 , A61K9/00 , A61K9/14 , A61K31/4439 , A61P1/04
CPC分类号： A61K9/2095 , A61K9/1676 , A61K9/282 , A61K9/2866 , A61K9/5042 , A61K31/4439
摘要： A benzimidazole formulation which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach, and which has low levels of residual volatile excipients, including but not limited to residual alkalinizing agents and/or residual solvents.
摘要翻译：一种苯并咪唑制剂，其缺乏中间层，而且在储存期间和在通过胃期间都是稳定的，并且具有低水平的残留挥发性赋形剂，包括但不限于残留的碱化剂和/或残留溶剂。

9. 发明申请

US20080260818A1 Controlled Absorption of Statins in the Intestine 审中-公开
标题翻译：他汀类药物在肠内的控制吸收
公开(公告)号：US20080260818A1
公开(公告)日：2008-10-23
申请号：US11909961
申请日：2006-03-27
申请人： Adel Penhasi , Marina Ruderman , Maxim Gomberg
发明人： Adel Penhasi , Marina Ruderman , Maxim Gomberg
IPC分类号： A61K9/24 , A61K9/16 , A61K9/22 , A61K9/52 , A61K9/28 , A61K9/32 , A61K9/36 , A61K9/56 , A61K9/58 , A61K9/62
CPC分类号： A61K31/00 , A61K9/2846 , A61K9/2866
摘要： The present invention provides a controlled absorption formulation in which modified release of active ingredient preferentially occurs in the lower gastrointestinal tract, including the colon. The formulation supports a significantly higher bioavailability of the active ingredient into the body of the subject than can be achieved from the currently used conventional formulation, such that therapeutically significant plasma levels of statin are maintained for an extended period after administration. The formulation preferably features a core over which an outer coating is layered. The core is optionally and preferentially in the form of a tablet.
摘要翻译：本发明提供了受控吸收制剂，其中活性成分的改性释放优先发生在下胃肠道，包括结肠中。制剂支持活性成分比目前使用的常规制剂可以获得的活性成分显着更高的生物利用度，使得他汀在施用后长时间内维持治疗上显着的血浆水平。制剂优选具有芯，其上层叠有外涂层。核心可选地且优选为片剂形式。

10. 发明授权

US08865198B2 Method for treating a periodontal disease 有权
标题翻译：治疗牙周病的方法
公开(公告)号：US08865198B2
公开(公告)日：2014-10-21
申请号：US13277784
申请日：2011-10-20
申请人： Avi Avramoff , Eyal Shoshani , Adel Penhasi , Dan Oren
发明人： Avi Avramoff , Eyal Shoshani , Adel Penhasi , Dan Oren
IPC分类号： A61F13/00 , A61K47/10 , A61K9/00 , A61K47/42 , A61K9/70 , A61K31/192
CPC分类号： A61K9/0063 , A61K9/7007 , A61K31/155 , A61K31/192 , A61K47/10 , A61K47/42
摘要： Provided is a method for treating a periodontal disease affecting a periodontal pocket of a patient. The method includes inserting an oral delivery device into the periodontal pocket at a frequency of about once every 4 days to about once every 6 weeks. The oral delivery device is a controlled release solid unit dosage form suitable for insertion into a periodontal pocket of a patient, including a therapeutically effective amount of at least one anti-inflammatory agent, at least one antibacterial agent, or the combination of at least one anti-inflammatory agent and at least one antibacterial agent.
摘要翻译：提供了一种治疗影响患者牙周袋的牙周病的方法。该方法包括将口服递送装置以大约每4天一次的频率插入牙周袋中，每六周约一次。口服递送装置是适于插入患者牙周袋的控释固体单元剂型，包括治疗有效量的至少一种抗炎剂，至少一种抗菌剂或至少一种抗微生物剂的组合抗炎剂和至少一种抗菌剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式